Blood Test for Factor IX Now Available in Canada, Other Countries
A blood test to determine the amount of active factor IX — the clotting factor that is missing in…
Articles by Margarida Maia, PhD
Switch to Kovaltry Seen to Better Protect Boys With Severe Hem A
Boys with severe hemophilia A who switched to Kovaltry (octocog alfa), which replaces a missing clotting protein called…
FDA Places ASC618, Gene Therapy for Hemophilia A, on Fast Track
The U.S. Food and Drug Administration (FDA) has given fast track designation to ASC618, an investigational one-time gene therapy for…
Foam Roller Eased Knee Pain, Improved Range of Motion
A foam roller to release tension in the fascia — a casing of fibrous tissue that surrounds and holds other…
Age and Hepatitis C Increase Risk of Diabetes for Hemophilia Patients
Diabetes, which causes blood sugar levels to rise too high, is less likely to develop in young men with…
Four Cases of Acquired Hem A Reported After 2nd COVID-19 Vaccine
Four people in a region of Northern Italy were diagnosed with acquired hemophilia A (AHA) weeks after receiving the second dose…
High COVID-19 Vaccination Rates, But Concerns, for Austrian Patients
In Austria, most patients with hemophilia have been vaccinated against COVID-19 — but some expressed concerns over the vaccine’s…
FLT180a for Hemophilia B Keeps Normal Factor IX Levels for 3+ Years
In a Phase 1/2 dose-finding study called B-AMAZE, FLT180a gene therapy from Freeline Therapeutics brought about sustained levels of…
Patients Express Gains in Switch to Extended Half-life Therapies
For some patients with moderate or severe hemophilia, switching from standard to extended half-life replacement therapy results in improvements…
Long-term Preventive Use of Esperoct Effective in Hemophilia A
Long-term prophylactic (preventive) treatment with a fixed dose of Esperoct (turoctocog alfa pegol) — approved in the U.S. and…